Eris Lifesciences Limited (ERIS.BO)
INR 1321.05
(3.6%)
INR 1321.05
(3.6%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 38.26 Billion INR | 164.53% |
| 2022 | 14.46 Billion INR | 297.5% |
| 2021 | 3.63 Billion INR | 40.87% |
| 2020 | 2.58 Billion INR | 0.93% |
| 2019 | 2.55 Billion INR | -33.49% |
| 2018 | 3.84 Billion INR | -32.97% |
| 2017 | 5.74 Billion INR | 323.0% |
| 2016 | 1.35 Billion INR | 43.57% |
| 2015 | 945.34 Million INR | 7.8% |
| 2014 | 876.95 Million INR | -2.28% |
| 2013 | 897.4 Million INR | 47.18% |
| 2012 | 609.72 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -32.22 Billion INR | -184.2% |
| 2024 Q2 | 38.44 Billion INR | 219.33% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 38.26 Billion INR | 164.53% |
| 2023 Q4 | 38.26 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 14.47 Billion INR | 0.0% |
| 2022 FY | 14.46 Billion INR | 297.5% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 8.11 Billion INR | 0.0% |
| 2022 Q4 | 14.46 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 3.63 Billion INR | 0.0% |
| 2021 FY | 3.63 Billion INR | 40.87% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 3.26 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 2.66 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 2.58 Billion INR | 0.93% |
| 2020 Q4 | 2.58 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 2.55 Billion INR | 0.0% |
| 2019 FY | 2.55 Billion INR | -33.49% |
| 2019 Q2 | 2.26 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 3.84 Billion INR | -32.97% |
| 2018 Q4 | 3.84 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 4.76 Billion INR | 0.0% |
| 2017 FY | 5.74 Billion INR | 323.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q4 | 5.74 Billion INR | 0.0% |
| 2017 Q2 | 1.54 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2016 Q2 | 965.48 Million INR | 0.0% |
| 2016 Q4 | 1.35 Billion INR | 0.0% |
| 2016 Q1 | - INR | 0.0% |
| 2016 FY | 1.35 Billion INR | 43.57% |
| 2015 FY | 945.34 Million INR | 7.8% |
| 2014 FY | 876.95 Million INR | -2.28% |
| 2013 FY | 897.4 Million INR | 47.18% |
| 2012 FY | 609.72 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | -135.151% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 74.858% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -638.637% |
| Granules India Limited | 22.95 Billion INR | -66.714% |
| Indoco Remedies Limited | 10.34 Billion INR | -270.015% |
| Achyut Healthcare Limited | 2.01 Million INR | -1900946.2% |
| Ajanta Pharma Limited | 10.71 Billion INR | -257.301% |
| Alkem Laboratories Limited | 48.6 Billion INR | 21.267% |
| Alpa Laboratories Limited | 307.12 Million INR | -12360.215% |
| Brooks Laboratories Limited | 248.6 Million INR | -15293.365% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -945.259% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -686.168% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -1714.64% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 64.225% |
| FDC Limited | 3.7 Billion INR | -931.704% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 41.226% |
| Gufic Biosciences Limited | 5.59 Billion INR | -583.381% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -1571.488% |
| Ipca Laboratories Limited | 33.74 Billion INR | -13.411% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -12795.289% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -1186.791% |
| Lasa Supergenerics Limited | 541.92 Million INR | -6961.505% |
| Laurus Labs Limited | 42.71 Billion INR | 10.41% |
| Lupin Limited | 96.23 Billion INR | 60.236% |
| Mankind Pharma Limited | 23.87 Billion INR | -60.287% |
| Medicamen Biotech Limited | 940.36 Million INR | -3969.481% |
| Medico Remedies Limited | 438.24 Million INR | -8632.136% |
| Megasoft Limited | 1.85 Billion INR | -1965.035% |
| NATCO Pharma Limited | 10.53 Billion INR | -263.35% |
| Piramal Pharma Limited | 74 Billion INR | 48.289% |
| RPG Life Sciences Limited | 1.38 Billion INR | -2672.646% |
| Sigachi Industries Limited | 2.53 Billion INR | -1411.816% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 79.153% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -1781.207% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -3184.217% |
| Unichem Laboratories Limited | 8.06 Billion INR | -374.245% |
| Wanbury Limited | 3.15 Billion INR | -1112.735% |
| Windlas Biotech Limited | 1.76 Billion INR | -2070.991% |
| ZIM Laboratories Limited | 2.08 Billion INR | -1739.137% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 46.696% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -883.022% |
| Divi's Laboratories Limited | 18.99 Billion INR | -101.517% |
| Hester Biosciences Limited | 3.59 Billion INR | -964.563% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -1394.146% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -4782.226% |
| Bal Pharma Limited | 2.51 Billion INR | -1423.849% |
| Strides Pharma Science Limited | 37.68 Billion INR | -1.559% |
| Venus Remedies Limited | 1.39 Billion INR | -2647.563% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -363.816% |
| Nectar Lifesciences Limited | 11.21 Billion INR | -241.128% |
| Shilpa Medicare Limited | 12.93 Billion INR | -195.907% |
| Aarti Drugs Limited | 11.5 Billion INR | -232.65% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -504.656% |
| Suven Life Sciences Limited | 148.62 Million INR | -25648.757% |
| Ind-Swift Limited | 13.45 Billion INR | -184.458% |
| Valiant Laboratories Limited | 1.05 Billion INR | -3516.134% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -257.378% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | -170.564% |
| Themis Medicare Limited | 1.88 Billion INR | -1927.435% |
| Hikal Limited | 12.99 Billion INR | -194.485% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 53.36% |
| Sequent Scientific Limited | 8.27 Billion INR | -362.496% |
| Novartis India Limited | 1.8 Billion INR | -2024.705% |
| Wockhardt Limited | 39.87 Billion INR | 4.018% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 37.546% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -13150.759% |
| Neuland Laboratories Limited | 5.49 Billion INR | -595.965% |
| Morepen Laboratories Limited | 4.45 Billion INR | -758.069% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -5843.325% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -1836.338% |